PLA2G6-associated neurodegeneration (PLAN): further expansion of the clinical, radiological and mutation spectrum associated with infantile and atypical childhood-onset disease

M A Illingworth, E Meyer, W K Chong, A Y Manzur, L J Carr, R Younis, C Hardy, F McDonald, A M Childs, B Stewart, D Warren, R Kneen, M D King, S J Hayflick, M A Kurian, M A Illingworth, E Meyer, W K Chong, A Y Manzur, L J Carr, R Younis, C Hardy, F McDonald, A M Childs, B Stewart, D Warren, R Kneen, M D King, S J Hayflick, M A Kurian

Abstract

Phospholipase A2 associated neurodegeneration (PLAN) is a major phenotype of autosomal recessive Neurodegeneration with Brain Iron Accumulation (NBIA). We describe the clinical phenotypes, neuroimaging features and PLA2G6 mutations in 5 children, of whom 4 presented with infantile neuroaxonal dystrophy (INAD). One other patient was diagnosed with the onset of PLAN in childhood, and our report highlights the diagnostic challenges associated with this atypical PLAN subtype. In this series, the neuroradiological relevance of classical PLAN features as well as apparent claval hypertrophy' is explored. Novel PLA2G6 mutations were identified in all patients. PLAN should be considered not only in patients presenting with a classic INAD phenotype but also in older patients presenting later in childhood with non-specific progressive neurological features including social communication difficulties, gait disturbance, dyspraxia, neuropsychiatric symptoms and extrapyramidal motor features.

Keywords: INAD; NBIA; Neurodegeneration with brain iron accumulation; PLA2G6; PLAN.

Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Figures

Fig. 1
Fig. 1
a. Midline sagittal T1 brain MRI of Case 1 at 27 months. b. Axial T2 weighted brain MRI of Case 1 aged 39 months, demonstrating iron deposition in the globus pallidus, which is absent on earlier imaging (a). c. Midline sagittal T1 brain MRI of Case 2 aged 33 months, demonstrating classical features of typical PLAN (symbol key and Table 3) and apparent claval hypertrophy. d. Axial T2* brain MRI of Case 2 aged 33 months, at the level of the globus pallidus; note the absence of iron deposition. e. Midline sagittal T1 brain MRI of Case 3 aged 4 years and 6 months, demonstrating classical features of typical PLAN and apparent claval hypertrophy. f. Axial FLAIR brain MRI of Case 3 aged 4 years and 6 months at level of cerebellum, showing high signal of the cerebellar cortex, indicative of gliosis. There is no iron deposition. g. Midline sagittal T1 brain MRI of Case 4 aged 22 months, demonstrating cerebellar atrophy, apparent claval hypertrophy and thin smooth splenium of the corpus callosum. h. Axial T2 weighted brain MRI of Case 4 aged 22 months, at the level of the globus pallidus. There is no iron deposition. i. Midline sagittal T1 brain MRI of Case 5 aged 11 years, demonstrating cerebellar atrophy and apparent claval hypertrophy. j. Axial T2 brain MRI of Case 5 aged 16 years demonstrating iron deposition in the globus pallidus. k. Axial T2 brain MRI of Case 5 aged 16 years demonstrating iron deposition in the substantia nigra. l. Midline sagittal T1 brain MRI of a 10 year old female with hemiplegic migraine and pathogenic CACNA1A mutation, demonstrating cerebellar atrophy and apparent claval hypertrophy.
Fig. 2
Fig. 2
Electroencephalogram, Case 2 EEG of Case 2, aged 29 months in wakefulness, demonstrating fast beta2 activity (indicated by the red oval shape).

References

    1. Kurian M.A., McNeill A., Lin J.P. Childhood disorders of neurodegeneration with brain iron accumulation. Dev. Med. Child Neurol. 2011;53:394–404.
    1. Gregory A., Westaway S.K., Holm I.E. Neurodegeneration associated with genetic defects in phospholipase A2. Neurology. 2008;71:1402–1409.
    1. Kurian M.A., Morgan N.V., MacPherson L. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN) Neurology. 2008;70:1623–1629.
    1. Gregory A., Polster B.J., Hayflick S. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J. Med. Genet. 2009;46(2):73–80.
    1. Hallervarden J., Spatz H. Eigenartige Erkrankung im extrapyramidalen System mit besonderer Beteiligung des Globus Pallidus und der Substantia nigra. Z. Ges. Neurol. Psychiat. 1922;79:254–302.
    1. Gregory A., Kurian M.A., Maher E.R. In: GeneReviews™ [Internet] Pagon R.A., Bird T.D., Dolan C.R., editors. University of Washington, Seattle; Seattle (WA); 1993. 2008 Jun 19 [Updated 2012 Apr 19]
    1. Hartig M.B., Luso A., Haack T. Absence of an orphan mitochondrial protein c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am. J. Hum. Genet. 2011;89 543-330.
    1. Haack T.B., Hogarth P., Kruer M.C. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct. X-linked dominant form of NBIA. Am. J. Hum. Genet. 2012;91(6):1144–1149.
    1. Morgan N.V., Westaway S.K., Morton J.E. PLA2G6, encoding a phospholipase A2 is mutated in neurodegenerative disorders with high brain iron. Nat. Genet. 2006;38:752–754.
    1. Paisan-Ruiz C., Bhatia K.P., Hernandez D. Characterisation of PLA2G6 as a locus for dystonia-parkinsonism. Ann. Neurol. 2009;65:19–23.
    1. Larsson P.K., Claesson H.E., Kennedy B.P. Multiple splice variants of the human calcium-independent phospholipase A2 and their effect on enzyme activity. J. Biol. Chem. 1998;273:207–214.
    1. Balsinde J., Balboa M.A. Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. Cell Signal. 2005;17:1052–1062.
    1. Strokin M., Seburn K.L., Cox G.A. Severe disturbance in the Ca2+ signalling on astrocytes from mouse models of human infantile neuroaxonal dystrophy with mutated PLA2G6. Hum. Mol. Genet. 2012;15:2807–2814.
    1. Wada H., Yasuda T., Miura I. Establishment of an improved mouse model for infantile neuroaxonal dystrophy that shows early disease onset and bears a point mutation in Pla2g6. Am. J. Pathol. 2009;175:2257–2263.
    1. Crompton D., Rehal P.K., MacPherson l. Multiplex ligation-dependent probe amplification (MLPA) analysis is an effective tool for the detection of novel intragenic PLA2G6 mutations: implications for molecular diagnosis. Mol. Genet. Metab. 2010;100:207–212.
    1. Yoshino H., Tomiyama H., Tachibana N. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology. 2010;75:1356–1361.
    1. Haverfield E.V., Dempsey M.A., Gregory A. 2008. Intragenic deletion and duplication analysis of the PANK2 and PLA2G6 genes in patients with NBIA; In ACMG Annual Clinical Genetics Meeting; Phoenix Arizona, USA.
    1. Maawali A., Yoon G., Halliday W. Hypertrophy of the clava, a new MRI sign in patients with PLA2G6 mutations. In; Poster presentation: American Society of Human Genetics Meeting October 2011. 2011
    1. Beck G., Sugira Y., Shinzawa K. Neuroaxonal dystrophy in calcium-independent phospholipase A2β deficiency results from insufficient remodelling and degeneration of mitochondrial and presynaptic membranes. J. Neurosci. 2011;31:11411–11420.
    1. Shinzawa K., Sumi H., Ikawa M. Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease. J. Neurosci. 2008;28:2212–2220.
    1. Malik I., Turk J., Mancusi D.J. Disrupted membrane homeostasis and accumulation of ubiquinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. J. Pathol. 2008;172:406–416.
    1. Federico A., Cardaioli E., Da Pozzo P. Mitochondria, oxidative stress and neurodegeneration. J. Neurol. Sci. 2012;322(1–2):254–262.
    1. Silah M.A., Mundwiller E., Khan A.O. New findings in a global approach to dissect the whole phenotype of PLA2G6 Gene mutations. PLoS One. 2013;8:e76831.
    1. Riku Y., Ikeuchi T., Yoshini H. Extensive aggregation of α-synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site. Acta Neuropathol. Commun. 2013;1:12.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj